

Please amend the subject application as follows:

In the Specification

NE On page 11, line 3, delete "innunodeficiency" and substitute --immunodeficiency-- therefor.

On page 12, line 24, delete "supranucleo" and substitute --supranuclear-- therefor.

On page 12, line 30, delete "abetalipoproteemia" and substitute --abetalipoproteinemia-- therefor.

On page 13, line 7, delete "Hallerrorden" and substitute --Hallervorden-- therefor.

On page 20, line 26, delete "1994)," insert --1994, now U.S. Patent No. 5,656,272)-- therefor.

On page 24, line 30, delete "Chimeric".

On page 24, delete lines 31-34.

A² On page 25, line 27, delete "1994)," insert --1994, now U.S. Patent No. 5,656,272)-- therefor.

On page 41, line 31, delete "Sandimmune®" and substitute --SANDIMMUNE®-- therefor.

A³ On page 51, line 8, delete "(FACScan," and substitute --using a flow cytometer sold under the trademark "FACScan" (--- therefor.

A⁴ On page 65, line 28, delete "Sandimmune®" and substitute --sold under the trademark SANDIMMUNE®-- therefor.

A⁵ On page 68, line 22, delete "Sandimmune®" and substitute --sold under the trademark SANDIMMUNE®-- therefor.

On page 70, line 20, delete "Sandimmune®" and substitute --SANDIMMUNE®-- therefor.

In the Claims

Please cancel Claims 1-14 and 31-45 and amend Claims 15-16, 18-21, 23-24 and 26-29 as follows:

A⁶ Acont 5. (Amended) A method [for] of treating [or preventing] rheumatoid arthritis in an individual in need thereof